MX387596B - Degradadores selectivos del receptor de estrógeno y sus usos. - Google Patents

Degradadores selectivos del receptor de estrógeno y sus usos.

Info

Publication number
MX387596B
MX387596B MX2018009496A MX2018009496A MX387596B MX 387596 B MX387596 B MX 387596B MX 2018009496 A MX2018009496 A MX 2018009496A MX 2018009496 A MX2018009496 A MX 2018009496A MX 387596 B MX387596 B MX 387596B
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
receptor degraders
formula
present disclosure
Prior art date
Application number
MX2018009496A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009496A (es
Inventor
Xing Dai
Yaolin Wang
Original Assignee
Inventisbio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Llc filed Critical Inventisbio Llc
Publication of MX2018009496A publication Critical patent/MX2018009496A/es
Publication of MX387596B publication Critical patent/MX387596B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2018009496A 2016-02-05 2017-02-03 Degradadores selectivos del receptor de estrógeno y sus usos. MX387596B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291921P 2016-02-05 2016-02-05
PCT/US2017/016452 WO2017136688A1 (en) 2016-02-05 2017-02-03 Selective estrogen receptor degraders and uses thereof

Publications (2)

Publication Number Publication Date
MX2018009496A MX2018009496A (es) 2018-12-11
MX387596B true MX387596B (es) 2025-03-18

Family

ID=59501091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009496A MX387596B (es) 2016-02-05 2017-02-03 Degradadores selectivos del receptor de estrógeno y sus usos.

Country Status (15)

Country Link
US (4) US10647724B2 (enExample)
EP (1) EP3411034B1 (enExample)
JP (1) JP6905539B2 (enExample)
KR (1) KR102479822B1 (enExample)
CN (2) CN109362222B (enExample)
AU (1) AU2017213614B2 (enExample)
BR (1) BR112018015419B1 (enExample)
CA (1) CA3012078C (enExample)
DK (1) DK3411034T3 (enExample)
ES (1) ES2842579T3 (enExample)
IL (1) IL260789B (enExample)
MX (1) MX387596B (enExample)
RU (1) RU2734501C2 (enExample)
WO (1) WO2017136688A1 (enExample)
ZA (1) ZA201805573B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171330A1 (es) 2014-12-18 2017-09-13 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos
CA3011391C (en) * 2015-11-12 2021-02-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
DK3411034T3 (da) 2016-02-05 2021-01-11 Inventisbio Inc Selektiv østrogenreceptornedbrydere og anvendelser deraf
JP6733872B2 (ja) * 2016-02-26 2020-08-05 ロンザ ウォーカーズヴィル，インコーポレーテッド 肝細胞を寄せ集める方法
EP3442971B1 (en) 2016-04-01 2024-09-25 Recurium IP Holdings, LLC Estrogen receptor modulators
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
JP7348906B2 (ja) 2018-02-28 2023-09-21 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP3810283B1 (en) 2018-06-21 2023-06-14 F. Hoffmann-La Roche AG Solid forms of the tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, process for their preparation and methods of their use in treating cancers
CN113490850B (zh) 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
MX2021007687A (es) * 2018-12-24 2021-10-13 Inventisbio Co Ltd Sales novedosas de degradadores selectivos de receptores de estrogeno.
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2020232119A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
US12345153B2 (en) 2022-08-12 2025-07-01 Saudi Arabian Oil Company Distributed fiber-optic telemetry for data transmission and real-time location of downhole autonomous sensing devices
CN119907798A (zh) * 2022-08-25 2025-04-29 赛诺菲 新颖的取代的2,3,4,9-四氢-1h-吡啶并[3,4-b]吲哚甲酸衍生物、其制备方法及其治疗用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516967A (ja) 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
WO2004091488A2 (en) 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
PL1737461T3 (pl) 2004-03-15 2013-05-31 Ptc Therapeutics Inc Pochodne karbolinowe użyteczne w hamowaniu angiogenezy
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US8703726B2 (en) * 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
JP2013508397A (ja) * 2009-10-22 2013-03-07 ポリメディックス・インコーポレーテッド 高分子化合物の調製方法
DK2580210T5 (en) 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
EP2791133B1 (en) * 2011-12-14 2019-04-17 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
US20140122109A1 (en) * 2012-10-29 2014-05-01 Consuli, Inc. Clinical diagnosis objects interaction
KR20150129723A (ko) * 2013-03-14 2015-11-20 세라곤 파마슈티컬스, 인크. 다환형 에스트로겐 수용체 조절제 및 이의 용도
PE20160874A1 (es) 2013-05-28 2016-09-04 Astrazeneca Ab Compuestos quimicos
CA2915534A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CA2941161A1 (en) * 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
EP3156054A4 (en) 2014-06-12 2018-03-14 ONO Pharmaceutical Co., Ltd. Medicine for preventing and/or treating stress-induced diseases
PE20171330A1 (es) * 2014-12-18 2017-09-13 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
EP3355884B1 (en) 2015-10-01 2021-04-28 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
CA3011391C (en) * 2015-11-12 2021-02-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
DK3411034T3 (da) 2016-02-05 2021-01-11 Inventisbio Inc Selektiv østrogenreceptornedbrydere og anvendelser deraf
EP3442971B1 (en) 2016-04-01 2024-09-25 Recurium IP Holdings, LLC Estrogen receptor modulators
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP7018026B2 (ja) 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
US10774081B2 (en) 2016-10-28 2020-09-15 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo substituted piperidine compound as estrogen receptor down-regulator
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
UA125043C2 (uk) 2017-01-30 2021-12-29 Астразенека Аб Модулятори рецептора естрогену
MX2021007687A (es) * 2018-12-24 2021-10-13 Inventisbio Co Ltd Sales novedosas de degradadores selectivos de receptores de estrogeno.

Also Published As

Publication number Publication date
US20210253592A1 (en) 2021-08-19
RU2018128318A3 (enExample) 2020-04-02
BR112018015419A2 (pt) 2018-12-18
NZ744516A (en) 2024-05-31
ES2842579T3 (es) 2021-07-14
EP3411034A4 (en) 2019-08-28
CA3012078C (en) 2024-01-30
US10647724B2 (en) 2020-05-12
RU2018128318A (ru) 2020-03-05
CN113004273A (zh) 2021-06-22
CA3012078A1 (en) 2017-08-10
AU2017213614A1 (en) 2018-08-09
BR112018015419B1 (pt) 2024-01-30
KR102479822B1 (ko) 2022-12-21
MX2018009496A (es) 2018-12-11
US12187736B2 (en) 2025-01-07
CN109362222A (zh) 2019-02-19
US20240043442A1 (en) 2024-02-08
CN109362222B (zh) 2021-03-19
US20200048250A1 (en) 2020-02-13
US11014936B2 (en) 2021-05-25
JP6905539B2 (ja) 2021-07-21
JP2019504890A (ja) 2019-02-21
IL260789B (en) 2021-03-25
ZA201805573B (en) 2020-12-23
RU2734501C2 (ru) 2020-10-19
DK3411034T3 (da) 2021-01-11
AU2017213614B2 (en) 2022-09-01
EP3411034A1 (en) 2018-12-12
WO2017136688A1 (en) 2017-08-10
US20200040001A1 (en) 2020-02-06
KR20180104161A (ko) 2018-09-19
EP3411034B1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX387596B (es) Degradadores selectivos del receptor de estrógeno y sus usos.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
MX391040B (es) Formulacion de alta concentracion.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CL2018001085A1 (es) Derivados de indolin-2-ona